Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: A meta-analysis

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 5, 2014, Pages 2113-2122

  Zhou, Zhenyu ^a   Chen, Chen ^a   Zhang, Jun ^a   Ji, Xinran ^b   Liu, Lifeng ^a   Zhang, Guichun ^a   Cao, Xuecheng ^a   Wang, Pingshan ^a  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Denosumab; Meta analysis; Osteoporosis; Postmenopausal women

Indexed keywords

BONE DENSITY CONSERVATION AGENT; DENOSUMAB; MONOCLONAL ANTIBODY;

AGE; BONE DENSITY; CHI SQUARE DISTRIBUTION; DRUG EFFECTS; FEMALE; HUMAN; META ANALYSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATHOPHYSIOLOGY; RISK; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME;

AGE FACTORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; ODDS RATIO; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 84902463543     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Rachner TD, Khosla S and Hofbauer LC. Osteoporosis:now and the future. Lancet 2011; 377: 1276-1287.
2. Rapuri PB, Gallagher JC and Haynatzka V. Protein intake: effects on bone mineral density and the rate of bone loss in elderly women. Am J Clin Nutr 2003; 77: 1517-1525.
3. Bock O and Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis- optimizing efficacy in clinical practice. Clin Interv Aging 2008; 3: 279.
4. Jang SN, Choi YH, Choi MG, Kang SH, Jeong JY, Choi YJ and Kim DH. Prevalence and associated factors of osteoporosis among postmenopausal women in Chuncheon: Hallym Aging Study (HAS). J Prev Med Public Health 2006; 39: 389-396.
5. Shao M and Liu QS. Quality of life in patients with postmenopausal osteoporosis. J Osteoporos 2000; 6: 58-58.
6. Kurth A and Pfeilschifter J. [Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in me. German Guidelines Update 2006]. Der Orthopade 2007; 36: 683.
7. Geusens P and Reid D. Newer drug treatments: Their effects on fracture prevention. Best Pract Res Clin Rheumatol 2005; 19: 983-989.
8. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman DG, Mundy GR and Boyce BF. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478-1487.
9. Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC and Van G. Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL. J Bone Miner Res 2009; 24: 182-195.
10. Lewiecki EM. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 2006; 6: 1041-50.
11. Delavallée L, Assier E, Semerano L, Bessis N and Boissier MC. Emerging applications of anticytokine vaccines. Expert Rev Vaccines 2008; 7: 1507-17.
12. Boyce BF and Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007; 9: S1.
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ and McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
14. Higgins JP, Green S and Collaboration C. Cochrane handbook for systematic reviews of interventions. Wiley Online Library, 2008.
15. Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557.
16. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y and San Martin J. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93: 2149-57.
17. Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M and Wang A. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765.
18. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, Martin JS and Bone HG. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25: 72-81.
19. Kumagai Y, Hasunuma T and Padhi D. A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. Bone 2011; 49: 1101-1107.
20. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S and Fitzpatrick LA. Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD. J Bone Miner Res 2007; 22: 1832-1841.
21. Nakamura T, Matsumoto T, Sugimoto T and Shiraki M. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporos Int 2012; 23: 1131-1140.
22. Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, Moffett A, Siddhanti S, Ferreira I and Ghelani P. Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy: A Randomized Open-Label Trial. Obstet Gynecol 2013; 121: 1291-1299.
23. Roux C, Hofbauer L, Ho P, Wark J, Zillikens M, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S and Papaioannou N. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study. Bone 2014; 58: 48-54.
24. Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK and Boutroy S. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010; 25: 1886-1894.
25. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M and Jun S. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875-4882.
26. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Álvaro-Gracia JM and Wang H. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24: 153-161.
27. Moen MD and Keam SJ. Denosumab. Drugs Aging 2011; 28: 63-82.
28. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC and Bekker PJ. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 1221-1228.
29. McClung M, Lewiecki E, Geller M, Bolognese M, Peacock M, Weinstein R, Ding B, Rockabrand E, Wagman R and Miller P. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 2013; 24: 227-235.
30. Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J and McClung MR. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 2011; 96: 394-402.
31. Canalis E. New treatment modalities in osteoporosis. Endocr Pract 2010; 16: 855-863.
32. Di Somma C. Medical Therapy in Porotic Patients 10. Interventional Neuroradiology of the Spine: Clinical Features, Diagnosis, and Therapy. 2013; pp: 117.
33. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T and Urade M. Bisphosphonate-related osteonecrosis of the jaw: position paper from the allied task force committee of Japanese society for bone and mineral research, Japan osteoporosis society, Japanese society of periodontology, Japanese society for oral and maxillofacial radiology, and Japanese society of oral and maxillofacial surgeons. J Bone Miner Metab 2010; 28: 365-383.
34. Anastasilakis AD, Toulis KA, Goulis DG, Polyzos SA, Delaroudis S, Giomisi A and Terpos E. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis:a systematic review and a meta-analysis. Horm Metab Res 2009; 41: 721-729.